Drugs / Hamsa-1™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00684970 | Mar 2009 → Feb 2014 | prostate carcinoma | Tiltan Pharma Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hamsa-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00684970 ↗ |
| Known as | TL-118 | “Once daily Hamsa-1™ TL-118” NCT00684970 ↗ |
| Route | Oral | “The product is formulated as an oral suspension” NCT00684970 ↗ |